Complete Genomics' (GNOM +5.3%) restructuring and postponement of capacity expansion are incremental positives for Illumina (ILMN +1.1%), observes Leerink Swann. The firm says v pricing in the whole human genome sequencing market could stabilize as a result of GNOM' actions.
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs